<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03278873</url>
  </required_header>
  <id_info>
    <org_study_id>MGT007</org_study_id>
    <secondary_id>2016-003856-59</secondary_id>
    <nct_id>NCT03278873</nct_id>
  </id_info>
  <brief_title>Long-Term Follow-Up Gene Therapy Study for Achromatopsia CNGB3</brief_title>
  <official_title>Long-term Follow-up Study of Participants Following an Open Label, Multi-centre, Phase I/II Dose Escalation Trial of a Recombinant Adeno-associated Virus Vector for Gene Therapy of Adults and Children With Achromatopsia Owing to Defects in CNGB3</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MeiraGTx UK II Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Syne Qua Non Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>EMAS Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>MeiraGTx UK II Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a longer-term follow-up study for patients who participated in a clinical trial
      of AAV - CNGB3 retinal gene therapy for patients with achromatopsia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The follow up study is designed to collect data on longer-term safety and efficacy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 27, 2017</start_date>
  <completion_date type="Anticipated">August 7, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 10, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events related to the treatment</measure>
    <time_frame>5 Years</time_frame>
    <description>longer term safety as the absence of ATIMP-related safety events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in the visual function</measure>
    <time_frame>5 years</time_frame>
    <description>Improvements in visual function as assessed by visual assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in retinal function</measure>
    <time_frame>5 years</time_frame>
    <description>Improvement in the retinal function as assessed by visual assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in quality of life</measure>
    <time_frame>5 years</time_frame>
    <description>Quality of life will be measured by QoL questionnaires</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Achromatopsia</condition>
  <arm_group>
    <arm_group_label>Biological-Low dose AAV - CNGB3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subretinal administration of a single low dose of range AAV - CNGB3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biological-medium dose AAV - CNGB3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subretinal administration of a single medium dose of range AAV - CNGB3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biological-high dose AAV - CNGB3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subretinal administration of a single high dose of range AAV - CNGB3</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AAV - CNGB3</intervention_name>
    <description>Comparison of different dosages of AAV-CNGB3</description>
    <arm_group_label>Biological-Low dose AAV - CNGB3</arm_group_label>
    <arm_group_label>Biological-medium dose AAV - CNGB3</arm_group_label>
    <arm_group_label>Biological-high dose AAV - CNGB3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Were enrolled and treated in the CNGB3 gene therapy trial for achromatopsia

          -  Are willing to adhere to the protocol and long-term follow-up

        Exclusion Criteria:

          -  Individuals will be excluded if they are unwilling or unable to meet with the
             requirements of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Julie Bakobaki</last_name>
    <phone>+44 (0)20 3866 4320</phone>
    <email>julie.bakobaki@meiragtx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anna Morka</last_name>
    <email>anna.morka@meiragtx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Moorfields Eye Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel Michaelides</last_name>
      <email>michel.michaelides@ucl.ac.uk</email>
    </contact>
    <investigator>
      <last_name>James Bainbridge, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michel Michaelides, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 16, 2017</study_first_submitted>
  <study_first_submitted_qc>September 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2017</study_first_posted>
  <last_update_submitted>December 15, 2017</last_update_submitted>
  <last_update_submitted_qc>December 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Color Vision Defects</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

